3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
6
Neoplasm Metastasis
6
Pancreatic Neoplasms
2
Lung Neoplasms
1
Lung Diseases
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Carboplatin
9
Pemetrexed
7
pembrolizumab
4
osimertinib
3
entinostat
3
Gemcitabine
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
camrelizumab
2
Paclitaxel
2
Erlotinib Hydrochloride
2
Cisplatin
2
Bronchoscopy
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
demcizumab
1
cobimetinib
1
ceralasertib
1
atezolizumab
1
alectinib
1
aflibercept
1
Vinorelbine
1
Toll-Like Receptor 1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Diseases
×
demcizumab
×
Clear all
NCT02259582
2020-09-09
DENALI
Mereo BioPharma
Phase 2
Completed
82 enrolled
10 charts